Your browser doesn't support javascript.
loading
Rapid microinduction of sublingual buprenorphine from methadone in an outpatient setting: "A case series".
Singh, Gurpreet; Sri Konakanchi, Jaya; Betsch, Brandon; Thapa, Aastha; Sethi, Roopa.
Afiliação
  • Singh G; Department of Psychiatry and Behavioral Sciences, University of Kansas Health System, Kansas City, Kan-sas.
  • Sri Konakanchi J; School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Betsch B; School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Thapa A; School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Sethi R; Department of Psychiatry and Behavioral Sciences, University of Kansas Health System, Kansas City, Kansas. ORCID: 0000-0003-4209-591X.
J Opioid Manag ; 17(7): 167-170, 2021.
Article em En | MEDLINE | ID: mdl-34520038
Buprenorphine (BPN), FDA approved for opioid use disorder (OUD), requires an induction protocol for the patient in mild to moderate withdrawal. This can be problematic in outpatient practice due to complicated medical management. An emerging technique in literature uses a novel approach, called microinduction. In this method, escalating microdoses of BPN are administered, without requiring the patient to stop the opioid agonist. Our addiction treatment center used a microdosing technique to transit patients from methadone to BPN, without requiring opioid abstinence. Our case series is novel as it was outpatient microinduction from methadone to BPN in 7 days or less.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Buprenorfina / Transtornos Relacionados ao Uso de Opioides Tipo de estudo: Guideline Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article